Emergent BioSolutions (EBS) Given Daily Media Sentiment Score of 0.10
News coverage about Emergent BioSolutions (NYSE:EBS) has been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Emergent BioSolutions earned a news impact score of 0.10 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 47.5351348894895 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
EBS has been the subject of several recent research reports. ValuEngine upgraded Emergent BioSolutions from a “hold” rating to a “buy” rating in a research report on Thursday, March 1st. Singular Research lifted their price target on Emergent BioSolutions from $45.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Chardan Capital lifted their price target on Emergent BioSolutions from $47.00 to $53.00 and gave the stock a “buy” rating in a research report on Tuesday, January 16th. Zacks Investment Research lowered Emergent BioSolutions from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 11th. Finally, Goldman Sachs initiated coverage on Emergent BioSolutions in a research report on Wednesday, January 24th. They issued a “neutral” rating and a $55.00 price target for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $52.80.
EBS opened at $53.73 on Tuesday. The stock has a market capitalization of $2,632.12, a P/E ratio of 28.28, a P/E/G ratio of 1.04 and a beta of 1.29. Emergent BioSolutions has a 12 month low of $28.11 and a 12 month high of $54.87. The company has a quick ratio of 3.42, a current ratio of 4.85 and a debt-to-equity ratio of 0.01.
Emergent BioSolutions declared that its Board of Directors has initiated a stock buyback plan on Thursday, March 22nd that allows the company to buyback $50.00 million in shares. This buyback authorization allows the biopharmaceutical company to reacquire shares of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s board of directors believes its shares are undervalued.
In other Emergent BioSolutions news, EVP Adam Havey sold 1,898 shares of the business’s stock in a transaction that occurred on Thursday, March 1st. The stock was sold at an average price of $49.50, for a total transaction of $93,951.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jerome M. Hauer sold 5,152 shares of the business’s stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $50.91, for a total value of $262,288.32. Following the transaction, the director now owns 23,797 shares of the company’s stock, valued at approximately $1,211,505.27. The disclosure for this sale can be found here. Insiders have sold 12,892 shares of company stock valued at $664,814 in the last 90 days. Company insiders own 16.50% of the company’s stock.
About Emergent BioSolutions
Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.
Receive News & Ratings for Emergent BioSolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent BioSolutions and related companies with MarketBeat.com's FREE daily email newsletter.